NASDAQ:RDHL RedHill Biopharma (RDHL) Stock Price, News & Analysis $6.50 +0.03 (+0.46%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About RedHill Biopharma Stock (NASDAQ:RDHL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RedHill Biopharma alerts:Sign Up Key Stats Today's Range$6.30▼$6.6850-Day Range$6.47▼$8.7852-Week Range$6.00▼$40.50Volume12,691 shsAverage Volume104,650 shsMarket Capitalization$8.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewRedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.Read More… RedHill Biopharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks9th Percentile Overall ScoreRDHL MarketRank™: RedHill Biopharma scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for RedHill Biopharma. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioRedHill Biopharma has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.44% of the float of RedHill Biopharma has been sold short.Short Interest Ratio / Days to CoverRedHill Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RedHill Biopharma has recently decreased by 17.65%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRedHill Biopharma does not currently pay a dividend.Dividend GrowthRedHill Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.44% of the float of RedHill Biopharma has been sold short.Short Interest Ratio / Days to CoverRedHill Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RedHill Biopharma has recently decreased by 17.65%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added RedHill Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, RedHill Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.81% of the stock of RedHill Biopharma is held by insiders.Percentage Held by InstitutionsOnly 7.20% of the stock of RedHill Biopharma is held by institutions.Read more about RedHill Biopharma's insider trading history. Receive RDHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address RDHL Stock News HeadlinesRadioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced DevelopmentDecember 10, 2024 | prnewswire.comRedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme CourtDecember 2, 2024 | prnewswire.comCrypto’s hidden gem + greatest crypto bull run in history = $$$?You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.December 21, 2024 | ProsperityPub (Ad)RedHill Biopharma to Present Opaganib at U.S. Defense ConferenceOctober 29, 2024 | markets.businessinsider.comRedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRNDOctober 28, 2024 | prnewswire.comRedHill Biopharma and Duke Collaborate on Opaganib DevelopmentOctober 22, 2024 | markets.businessinsider.comRedHill Biopharma signs research pact with Duke University School of MedicineOctober 22, 2024 | markets.businessinsider.comRedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation InjuryOctober 22, 2024 | prnewswire.comSee More Headlines RDHL Stock Analysis - Frequently Asked Questions How have RDHL shares performed this year? RedHill Biopharma's stock was trading at $912.50 at the beginning of the year. Since then, RDHL stock has decreased by 99.3% and is now trading at $6.50. View the best growth stocks for 2024 here. How were RedHill Biopharma's earnings last quarter? RedHill Biopharma Ltd. (NASDAQ:RDHL) issued its earnings results on Tuesday, November, 30th. The biotechnology company reported ($500.00) EPS for the quarter, missing analysts' consensus estimates of ($480.00) by $20.00. The biotechnology company earned $21.61 million during the quarter, compared to analysts' expectations of $23.41 million. When did RedHill Biopharma's stock split? RedHill Biopharma's stock reverse split on the morning of Tuesday, August 20th 2024. The 1-25 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 19th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of RedHill Biopharma? Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of RedHill Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that RedHill Biopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), CymaBay Therapeutics (CBAY) and AbbVie (ABBV). Company Calendar Last Earnings11/30/2021Today12/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RDHL Previous SymbolASX:RDH CUSIPN/A CIK1553846 Webwww.redhillbio.com Phone972-3541-3131Fax972-3541-3144Employees210Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.74 Quick Ratio0.56 Sales & Book Value Annual Sales$3.71 million Price / Sales2.25 Cash Flow$650.00 per share Price / Cash Flow0.01 Book Value$40.58 per share Price / Book0.16Miscellaneous Outstanding Shares1,281,000Free Float1,194,000Market Cap$8.33 million OptionableNo Data Beta3.65 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:RDHL) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RedHill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share RedHill Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
